Hernández CLE, Magaña MR

Language: Spanish
References: 10
Page: 3-7
PDF size: 65.10 Kb.

ABSTRACT

Objective: To determine whether subcutaneous administration of histamine phosphate relieves the lesions of patients with chronic idiopathic urticaria.
Methods: We identified 43 patients with clinical diagnostic criteria for chronic idiopathic urticaria by applying the questionnaire. Patientes were receiving drug therapy (loratadine, prednisone, montelukast, or combined), at least two months before the study without any change of the signs and/or symptoms of the patients. The variables analyzed were: intensity, duration, and consumption of drugs. Treatment consisted of subcutaneous administration of histamine starting with 0.1 mL (1 mcg) increasing to 0.5 mL (5 mcg), two times per week for a maximum period of six months. An ANOVA test was ample road Friedman ranges for evaluating the differences between baseline data and findings.
Results: Statistical analysis showed significant difference between baseline values and those found at two and six months after treatment (p ‹ 0.05); 65% of patients reported complete remission of lesions.
Conclusions: This study provides evidence of the safety and efficacy of histamine applied subcutaneously, which represents an alternative therapy in patients resistant to conventional drugs in the treatment of chronic idiopathic urticaria.

REFERENCES

1. Hein R. Chronic urticaria: impact of allergic inflammation. Allergy 2002;57(Suppl. 75):19-24.

2. Brodell L, Beck L. Fisiopatología de la urticaria crónica. Ann Allergy Asthma Immunol 2008;100:291-298.

3. Krueger KM, Witte D, Miller T, Barajas J, et al. G proteindependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations. J Pharmacol Experimental Ther 2005;314(1):271-281.

4. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983;302(5911):832-837.

5. Millán R, Trujillo B, Tene C. Histamina subcutánea en profilaxis de migraña. Efectos iniciales y seguimiento a largo plazo. Neurología 2006;21(2):55-59.

6. Passani MB, Lin JS, Hancock A, Crochet S, Blandina P. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004;25(12):618-625.

7. Levi R, Smith NC. Histamine H3-receptors: a new frontier in myocardial ischemia (abstract). J Pharmacol Exp Ther 2000;292(3):825-830.

8. Montes M, Rego R, Martínez M, López M, Betancourt J. Histamina, receptores y antagonistas. Rev Med Hops Gen Mex 2005;68(3):104-109.

9. Staumont-Sallé D, Piette F, Delaporte E. Etiological diagnosis and treatment of chronic urticaria. Rev Med Intern 2003;249(1):34-44.

10. Ljung O. Metroprolol in migraine. Cephalalgia 1981;1:142.